Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma in RelapseMultiple Myeloma, Refractory
- Interventions
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT04287855
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Biological: Autologous Stem Cell Transplant (ASCT)
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 310
- Registration Number
- NCT04268498
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Christian Buske
- Target Recruit Count
- 99
- Registration Number
- NCT04263480
- Locations
- 🇦🇹
Uniklinikum Salzburg, Salzburg, Austria
🇩🇪Kath. St.-Johannes-Gesellschaft Dortmund gGmbH, Dortmund, Germany
🇩🇪OncoResearch Lerchenfeld GmbH, Hamburg, Germany
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 54
- Registration Number
- NCT04191616
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille Cedex, France
🇬🇷University Hospital of Ioannina, Ioannina, Greece
🇮🇹Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II, Lecce, Italy
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Conditions
- Multiple MyelomaRefractory Multiple MyelomaMultiple Myeloma in RelapseRelapse
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Andrew Yee, MD
- Target Recruit Count
- 43
- Registration Number
- NCT04176718
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 19
- Registration Number
- NCT04163107
- Locations
- 🇳🇴
St. Olavs Hospital, Department of Hematology, Trondheim, Norway
🇳🇴Oslo University Hospital, Department of Hematology, Oslo Myeloma Center, Oslo, Norway
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
- Conditions
- Multiple MyelomaNew Diagnosis Tumor
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 84
- Registration Number
- NCT04096066
- Locations
- 🇮🇹
Ospedali Riuniti, Bergamo, Italy
🇮🇹AO di Padova, Padova, Italy
🇮🇹AO Bianchi Melacrino Morelli, Reggio Calabria, Italy
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
- Conditions
- Myeloma, Plasma-CellMyeloma-MultipleMyeloma MultiplePlasma Cell Myeloma
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT04065789
- Locations
- 🇮🇱
Hematology Department Sourasky Medical Center, Tel Aviv, Israel
🇮🇱Soroka Medical Center, Be'er Sheva, Israel
🇮🇱Kaplan Medical center, Reẖovot, Israel
Carfilzomib in Combination for the Treatment of RR MM
- Conditions
- Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Black Sea Hematology Association
- Target Recruit Count
- 300
- Registration Number
- NCT04004338
- Locations
- 🇹🇷
19 Mayıs University Faculty of Medicine, Samsun, Turkey
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 424
- Registration Number
- NCT03989414
- Locations
- 🇺🇸
Local Institution - 110, Winston-Salem, North Carolina, United States
🇨🇿Local Institution - 802, Brno, Czechia
🇨🇿Local Institution - 801, Ostrava-Poruba, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.